301 related articles for article (PubMed ID: 15192151)
1. Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model.
Tezval H; Jahn O; Todorovic C; Sasse A; Eckart K; Spiess J
Proc Natl Acad Sci U S A; 2004 Jun; 101(25):9468-73. PubMed ID: 15192151
[TBL] [Abstract][Full Text] [Related]
2. The role of CRF receptors in anxiety and depression: implications of the novel CRF1 agonist cortagine.
Todorovic C; Jahn O; Tezval H; Hippel C; Spiess J
Neurosci Biobehav Rev; 2005; 29(8):1323-33. PubMed ID: 16099044
[TBL] [Abstract][Full Text] [Related]
3. Region specific gene expression profile in mouse brain after chronic corticotropin releasing factor receptor 1 activation: the novel role for diazepam binding inhibitor in contextual fear conditioning.
Sherrin T; Blank T; Saravana R; Rayner M; Spiess J; Todorovic C
Neuroscience; 2009 Aug; 162(1):14-22. PubMed ID: 19362130
[TBL] [Abstract][Full Text] [Related]
4. Cortagine: behavioral and autonomic function of the selective CRF receptor subtype 1 agonist.
Farrokhi CB; Tovote P; Blanchard RJ; Blanchard DC; Litvin Y; Spiess J
CNS Drug Rev; 2007; 13(4):423-43. PubMed ID: 18078427
[TBL] [Abstract][Full Text] [Related]
5. Chronic stimulation of corticotropin-releasing factor receptor 1 enhances the anxiogenic response of the cholecystokinin system.
Sherrin T; Todorovic C; Zeyda T; Tan CH; Wong PT; Zhu YZ; Spiess J
Mol Psychiatry; 2009 Mar; 14(3):291-307. PubMed ID: 18195718
[TBL] [Abstract][Full Text] [Related]
6. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
Myers DA; Trinh JV; Myers TR
Mol Cell Endocrinol; 1998 Sep; 144(1-2):21-35. PubMed ID: 9863624
[TBL] [Abstract][Full Text] [Related]
7. Activation of central CRF receptor 1 by cortagine results in enhanced passive coping with a naturalistic threat in mice.
Tovote P; Farrokhi CB; Gonzales RM; Schnitzbauer U; Blanchard DC; Blanchard RJ; Spiess J
Psychoneuroendocrinology; 2010 Jul; 35(6):887-95. PubMed ID: 20036073
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety.
Todorovic C; Radulovic J; Jahn O; Radulovic M; Sherrin T; Hippel C; Spiess J
Eur J Neurosci; 2007 Jun; 25(11):3385-97. PubMed ID: 17553007
[TBL] [Abstract][Full Text] [Related]
9. Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30.
Rühmann A; Bonk I; Lin CR; Rosenfeld MG; Spiess J
Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15264-9. PubMed ID: 9860957
[TBL] [Abstract][Full Text] [Related]
10. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
Grigoriadis DE; Liu XJ; Vaughn J; Palmer SF; True CD; Vale WW; Ling N; De Souza EB
Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
[TBL] [Abstract][Full Text] [Related]
11. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.
Eckart K; Jahn O; Radulovic J; Tezval H; van Werven L; Spiess J
Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11142-7. PubMed ID: 11572971
[TBL] [Abstract][Full Text] [Related]
12. Human urocortin 2, a corticotropin-releasing factor (CRF)2 agonist, and ovine CRF, a CRF1 agonist, differentially alter feeding and motor activity.
Zorrilla EP; Reinhardt LE; Valdez GR; Inoue K; Rivier JE; Vale WW; Koob GF
J Pharmacol Exp Ther; 2004 Sep; 310(3):1027-34. PubMed ID: 15115804
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
Perrin MH; Tan LA; Vaughan JM; Lewis KA; Donaldson CJ; Miller C; Erchegyi J; Rivier JE; Sawchenko PE
J Pharmacol Exp Ther; 2015 May; 353(2):307-17. PubMed ID: 25736419
[TBL] [Abstract][Full Text] [Related]
14. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides.
Behan DP; De Souza EB; Lowry PJ; Potter E; Sawchenko P; Vale WW
Front Neuroendocrinol; 1995 Oct; 16(4):362-82. PubMed ID: 8557170
[TBL] [Abstract][Full Text] [Related]
15. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
Primus RJ; Yevich E; Baltazar C; Gallager DW
Neuropsychopharmacology; 1997 Nov; 17(5):308-16. PubMed ID: 9348546
[TBL] [Abstract][Full Text] [Related]
16. Corticotropin-releasing factor receptor 1 and central heart rate regulation in mice during expression of conditioned fear.
Stiedl O; Meyer M; Jahn O; Ogren SO; Spiess J
J Pharmacol Exp Ther; 2005 Mar; 312(3):905-16. PubMed ID: 15537825
[TBL] [Abstract][Full Text] [Related]
17. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
[TBL] [Abstract][Full Text] [Related]
18. The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.
Lawrence AJ; Krstew EV; Dautzenberg FM; Rühmann A
Br J Pharmacol; 2002 Jul; 136(6):896-904. PubMed ID: 12110614
[TBL] [Abstract][Full Text] [Related]
19. Novel high-affinity photoactivatable antagonists of corticotropin-releasing factor (CRF) photoaffinity labeling studies on CRF receptor, type 1 (CRFR1).
Bonk I; Rühmann A
Eur J Biochem; 2000 May; 267(10):3017-24. PubMed ID: 10806401
[TBL] [Abstract][Full Text] [Related]
20. Effects of ovine CRF injections into the dorsomedial, dorsolateral and lateral columns of the periaqueductal gray: a functional role for the dorsomedial column.
Borelli KG; Brandão ML
Horm Behav; 2008 Jan; 53(1):40-50. PubMed ID: 17920596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
